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Background: Pulmonary decline accelerates in cystic fibrosis-related diabetes (CFRD) proportional to severity of glucose intolerance, but
mechanisms are unclear. In people without CF, airway glucose (AG) concentrations are elevated when blood glucose (BG)≥8 mmol L−1
(airway threshold), and are associated with acquisition of respiratory infection.
Methods: To determine the relationship between BG and AG, 40 CF patients underwent paired BG and AG (nasal) measurements. Daily time
with BG>airway threshold was compared in 10 CFRD, 10 CF patients with normal glucose tolerance (CF-NGT) and 10 healthy volunteers by
continuous BGmonitoring. The effect of glucose at airway concentrations on bacterial growth was determined in vitro by optical densitometry.
Results: AG was present more frequently (85%-vs.-19%, p<0.0001) and at higher concentrations (0.5–3 mmol L−1-vs.-0.5–1 mmol L−1,
p<0.0001) when BG was ≥8 mmol L−1-vs.-<8 mmol L−1. Daily time with BG≥8 mmol L−1 was CFRD (49±25%), CF-NGT (6±5%),
healthy volunteers (1±3%), p<0.0001. Staphylococcus aureus growth increased at ≥0.5 mmol L−1 (p=0.006) and Pseudomonas
aeruginosa growth above 1–4 mmol L−1 glucose (p=0.039).
Conclusions: BG≥8 mmol L−1 predicted elevated AG concentrations in CF, at least in nasal secretions. CFRD patients spent ∼ 50% day
with BG>airway threshold, implying persistently elevated AG concentrations. Further studies are required to determine whether elevated
airway glucose concentrations contribute to accelerated pulmonary decline in CFRD.
© 2006 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Diabetes mellitus; Staphylococcus aureus; Pseudomonas aeruginosa; Nasal glucose; Continuous glucose monitoringAbbreviations: CF, cystic fibrosis; FEV1, forced expiratory volume in
1 s; FVC, forced vital capacity; CFRD, cystic fibrosis related diabetes; CF-
NGT, cystic fibrosis-normal glucose tolerance; HbA1c, glycosylated
haemoglobin; CGMS, continuous glucose monitoring system; NPB, nutrient
peptone broth; OD, optical densitometry; SGLT, sodium–glucose co-
transporter; ICU, intensive care unit; MRSA, methicillin-resistant Staphy-
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In cystic fibrosis (CF), reduced clearance of viscous lung
secretions causes progressive infection, inflammation and
declining lung function, which is the major cause of
morbidity and mortality. Changes in the composition of
pancreatic secretions cause ductal obstruction, leading to
loss of pancreatic tissue [1], including β islets which produce
insulin [2]. CF is thus commonly complicated by diabetes
mellitus and glucose intolerance. The prevalence of CF-
related diabetes increases with age, affecting more than 25%
CF patients over the age of 20 [3].ed by Elsevier B.V. All rights reserved.
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mortality than CF patients without diabetes [4]. The increase
in mortality may be attributable to an effect of diabetes on
pulmonary disease. On cross-sectional analysis of the
European Epidemiologic CF Registry, FEV1% predicted
was lower at all age groups in patients with CF-related
diabetes compared to CF patients without diabetes [5]. FEV1
and FVC were already 20% and 10% lower in CF-related
diabetes than in matched CF controls without diabetes 6
years prior to the onset of diabetes, implying pre-diabetic
acceleration in pulmonary decline [6].
Mechanisms underlying pre-diabetic and diabetic effects
on lung function in CF are poorly understood. However, as
rate of pulmonary decline is directly proportional to severity
of glucose intolerance, increased glucose concentrations may
play a role [7]. We have recently shown that, whilst glucose
is normally undetectable in human airway secretions, airway
glucose becomes detectable in healthy volunteers when
blood glucose is raised experimentally above 7.9±1.1 mmol
L−1 [8]. We also detected glucose at concentrations of 4 (2–
7, median (interquartile range)) mmol L−1 in nasal secretions
from people with diabetes mellitus and from 1 to 11 mmol
L−1 (range) in bronchial aspirates from people with acute
hyperglycaemia intubated on intensive care [9]. Seventy
percent of the intensive care patients with a blood
glucose≥ 8 mmol L− 1 and 100% with a blood
glucose>10 mmol L−1, but only 16% of patients with
blood glucose<8 mmol L−1 had glucose detected in
bronchial aspirates. Taken together these results support
the concept of a blood glucose ‘threshold’, above which
glucose becomes detectable in airway secretions. Glucose in
bronchial aspirates was significantly associated with acquisi-
tion of respiratory pathogens, particularly methicillin-
resistant Staphylococcus aureus [10]. Glucose in airway
secretions preceded and therefore could have precipitated
bacterial colonisation or infection, possibly by promoting
bacterial growth or impeding host immunity.
We hypothesised that airway glucose concentrations would
be elevated in CF patients when blood glucose exceeded the
airway threshold (≥8 mmol L−1), which would occur for
increasing proportions of the day as glucose intolerance
worsened. Glucose at these concentrations in airway secretions
could affect the growth of respiratory pathogens. To test this
we confirmed that airway glucose was elevated in people with
CF at blood glucose≥8 mmol L−1 and used continuous
glucose monitoring to determine the proportion of the day that
blood glucose exceeded the airway threshold. We examined
the relationship between airway glucose and in vitro growth of
S. aureus and Pseudomonas aeruginosa.
2. Methods
2.1. In vivo studies
Studies in human participants were approved by the
Royal Brompton Hospital and Wandsworth Local ResearchEthics Committees and conducted in accordance with the
Declaration of Helsinki. All participants gave written
informed consent for their inclusion in the study.
2.1.1. In vivo study 1. Relationship between blood and
airway glucose concentrations in cystic fibrosis
2.1.1.1. Participants. Blood and nasal glucose measure-
ments were compared to determine whether airway glucose
concentrations were elevated in CF patients when blood
glucose exceeded the airway threshold (≥8 mmol L−1) [8].
Forty CF patients were recruited during attendance at the
Department of Cystic Fibrosis, Royal Brompton Hospital.
Participants had CF diagnosed by positive sweat test and
clinical features, with or without genotype confirmation. CF
patients with and without related diabetes were included to
ensure a wide range of blood glucose concentrations. CF
patients were excluded if they had nasal polyps, acute rhinitis
or nasal symptoms or visible nasal inflammation on
inspection.
2.1.1.2. Protocol. Participants were studied on a single
occasion. Clinical information was collected and capillary
blood and nasal glucose measurements were both made
within 10 min of each other.
2.1.2. In vivo study 2. Proportion of the day spent with
blood glucose above the airway threshold
2.1.2.1. Participants. The proportion of the day spent with
blood glucose above the airway threshold (≥8 mmol L−1)
was compared between 10 CF patients with related diabetes,
10 CF patients with normal glucose tolerance and 10 healthy,
matched controls.
CF patients (diagnosed and recruited as described) were
included in the study if they had stable disease, defined as no
hospital admissions, no intravenous antibiotics, no change in
systemic steroid dose and no new enteral feeding in previous
6 weeks. Pregnant CF patients were excluded. Diabetes was
defined as either a prior diagnosis of CF-related diabetes
requiring treatment, or by oral glucose tolerance test [11].
Healthy volunteers were medical students or health care
workers without cystic fibrosis matched for age and body
mass index. Healthy volunteers did not have nasal or lung
disease, diabetes mellitus or first degree relatives with
diabetes.
2.1.2.2. Protocol. Participants without a prior diagnosis of
diabetes mellitus underwent oral glucose tolerance testing to
establish glucose tolerance [11]. All participants then
underwent continuous interstitial glucose monitoring over
48 h.
2.1.3. Experimental techniques
Clinical information: Age, gender, body mass index and
glycosylated haemoglobin (HbA1c) were recorded for CF
Table 1
Characteristics of CF patients undergoing paired blood and nasal glucose
measurements
Characteristic Patients
Number 40
Age (years) 30.3±9.4
Gender (M:F) 22:18
Body mass index (kg/m2) 21.9±2.6
FEV1 % predicted 51±21
CRP (mg/l) 17.8±20.9 (n=23)
White cell count (×109/l) 11.9±4.8 (n=30)
Fig. 1. Comparison between blood and nasal glucose concentrations in
cystic fibrosis patients. Nasal glucose measurements are shown for 40
people with cystic fibrosis who have a range of blood glucose concentra-
tions. The line denotes a blood glucose concentration of 7.9 mmol L−1, the
predicted airway glucose threshold [8]. Blood glucose was significantly
correlated with nasal glucose (R=0.464, p=0.003).
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white cell count and C-reactive protein were documented for
CF patients.
Airway glucose concentrations were measured in nasal
secretions using glucose oxidase sticks. Sticks were placed
on the nasal mucosa under direct vision for 30 s, checked for
adequate coating with nasal secretions and read in
comparison with a visual colour chart [9]. Nasal mucosa
was inspected prior to stick placement to exclude partici-
pants with clinical inflammation.
Capillary blood glucose was measured using Accu-Chek
Advantage (Roche Diagnostics Ltd).
Oral glucose tolerance testing was performed after ≥8 h
fasting. Venous plasma glucose was measured before and 2 h
after oral ingestion of 1.75 g/kg body weight (max 75 g)
glucose in 250 ml water.
Continuous Glucose Monitoring was performed using
Minimed Continuous Glucose Monitoring System (CGMS).
A glucose oxidase-based electrode measured interstitial
glucose every 10 s and the monitor reported average
readings every 5 min. Interstitial values were calibrated
against capillary blood glucose at least 3 times/24 h.
Participants were monitored for 48 h and the middle
continuous 24-hour period was used for analysis using
Minimed CGMS Solutions Software version 3.0A.
2.2. Microbiology
2.2.1. Bacterial strains
S. aureus (National Collection of Type Cultures 6571)
and Ps. aeruginosa (American Type Culture Collection
27853) were cultured from freezer stocks on Columbia
agar plates with 5% horse blood. Growth was examined
after overnight incubation at 37 °C in air to confirm
culture purity.
2.2.2. Experimental techniques
Bacteria were cultured in air overnight at 37 °C in
20 ml nutrient peptone broth (NPB) containing 20 mmol
L−1 glucose, centrifuged at 2400 g for 15 min, washed
then re-suspended in NPB without glucose. 4×107 colony
forming units of bacteria were suspended in 2 ml NPB in
cuvettes containing glucose at final concentrations of 0–
10 mmol L−1. Experiments were repeated 5 times for S.aureus and Ps. aeruginosa at the full range of glucose
concentrations.
After 0, 1, 3, 6, 24 and 48 h of culture, cultures were
agitated to ensure suspension using a 1 ml pipette and
bacterial growth was assessed using optical densitometry
(OD620) [12]. After 24 and 48 h of growth OD620 for bacteria
grown at each glucose concentration was divided by OD620
for bacteria grown without glucose to calculate growth
ratios.
2.2.3. Analysis
Values are given as mean±standard deviation and were
compared between 2 groups using unpaired t tests and more
than 2 groups using one way analysis of variance with post-
hoc Bonferroni analysis. Categorical variables are expressed
as numbers and percentages and were compared between
groups using χ2 tests. Pearson correlation was used to
describe relationships between continuous variables.
P<0.05 was considered significant. Statistical package for
the social sciences version 11.5 was used for analysis.
3. Results
3.1. In vivo study 1. Relationship between blood and airway
glucose concentrations
Clinical characteristics of 40 CF patients studied are given
in Table 1 and paired blood and nasal glucose measurements
are shown in Fig. 1. Glucose was detected in nasal secretions
from 16/40 people. People with glucose in nasal secretions
had significantly higher blood glucose concentrations (9.5±
3.2 mmol L−1) than people without glucose in nasal
secretions (6.3±3.6 mmol L−1, p=0.007). Thirteen out of
Table 2
Demographic characteristics of people undergoing blood glucose
monitoring
Healthy
volunteers
(n=10)
CF NGT
(n=10)
CFRD
(n=10)
P value
(analysis of
variance)
Age (years) 25.6±3.3 27.7±7.0 31.7±10.3 0.198
Gender (M:F) 7:3 6:4 7:3 0.861
Body mass index
(kg/m2)
22.0±2.1 22.6±2.3 21.7±2.4 0.660
FEV1 %
predicted
Not tested 64.2±22.9 51.6±18.8 0.196
Fasting blood
glucose (OGTT,
mmol L−1)
5.3±0.4 4.8±0.7 Not tested 0.073
Two-hour blood
glucose (OGTT,
mmol L−1)
5.7±1.2 5.9±1.1 Not tested 0.683
HbA1c (%) 5.1±0.2 5.3±0.5 7.0±1.5
a <0.0001
Nasal glucose
(% positive)
0 (n=6) 10 50 0.033
Oral glucose tolerance test (OGTT) results are given for CF patients with
normal glucose tolerance (CF-NGT) and healthy volunteers, as OGTTs were
used to confirm normal glucose tolerance in these groups. The majority of
people with CF-related diabetes (CFRD) were recruited on the basis of an
established diagnosis, hence did not undergo OGTT.
a Post-hoc Bonferroni analysis demonstrated that the difference detected
between groups in HbA1c by one way analysis of variance were
significant between people with cystic fibrosis-related diabetes and both
cystic fibrosis-normal glucose tolerance and healthy volunteers, but not
between people with cystic fibrosis-normal glucose tolerance and healthy
volunteers.
Fig. 2. Representative 24-hour blood glucose profiles. Representative 24-
hour glucose profiles from the middle monitored day are shown for A) a
healthy volunteer, B) a person with cystic fibrosis and normal glucose
tolerance and C) cystic fibrosis related diabetes. The bold line denotes sensor
blood glucose values plotted against time. The dotted line denotes the
predicted airway glucose threshold.
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had glucose in nasal secretions. 27/40 people had blood
glucose<8 mmol L−1, 5 (19%) of whom had glucose in nasal
secretions (p<0.0001). Nasal glucose concentrations were
higher in people with blood glucose≥8 mmol L−1 (1.2±
0.9 mmol L−1, range 0.5–3 mmol L−1) than in those with
blood glucose<8 mmol L−1 (0.1±0.3 mmol L−1, range
0.5–1 mmol L−1) (p<0.0001). Blood glucose was sig-
nificantly correlated with nasal glucose concentrations
(n=40, R=0.464, p=0.003).
3.2. In vivo study 2. Proportion of the day spent with
interstitial glucose above the airway threshold
Demographic characteristics of 10 CF patients with
related diabetes, 10 CF patients with normal glucose
tolerance and 10 healthy volunteers undergoing continuous
glucose monitoring are shown in Table 2. There were no
significant differences in age, gender or body mass index
between the 3 groups.
Normal glucose tolerance was confirmed in healthy
volunteers and CF-normal glucose tolerance by oral
glucose tolerance testing, requiring fasting blood glucose<
7.0 mmol L−1 and blood glucose<7.8 mmol L−1 2 h after
an oral glucose load (Table 2) [11]. Nine people
allocated to the CF-related diabetes group had a prior
diagnosis of CF-related diabetes and one was identifiedby oral glucose tolerance testing, having a 2-hour blood
glucose of 11.5 mmol L−1. HbA1c values were elevated
in people with CF-related diabetes, confirming long term
elevation of blood glucose, but were normal in healthy
volunteers and people with CF-normal glucose tolerance
(Table 2).
3.2.1. Continuous glucose monitoring
Representative interstitial glucose profiles from the
middle 24 h of the monitored period are shown for
healthy volunteers, CF-normal glucose tolerance and CF-
related diabetes in Fig. 2. People with CF-related
diabetes spent 49±25%, people with CF-normal glucose
tolerance spent 6±5% and healthy volunteers spent 1±
3% of the day with interstitial glucose above the airway
glucose threshold (≥8 mmol L−1) [8], analysis of
Fig. 3. Boxplot showing the proportion of the day spent by monitored
groups with blood glucose above the airway glucose threshold (≥8 mmol
L−1). The boxplot shows median, quartiles and extreme values (⁎) of the
proportion of 24 h spent by each group with blood glucose above the
airway glucose threshold. 10 subjects were studied in each group. One
way analysis of variance demonstrated significant differences in the
proportion of the day spent by each group with blood glucose above the
threshold (p<0.0001). Post-hoc Bonferroni analysis showed that the
proportion of the day spent with blood glucose above the airway threshold
was significantly greater in CF-related diabetes than CF-normal glucose
tolerance (p<0.0001) and healthy volunteers (p<0.0001) but was not
significantly different between CF-normal glucose tolerance and healthy
volunteers.
Fig. 4. Bar chart showing the effect of glucose concentration and time on
bacterial growth. Bacterial growth quantified using optical density is shown
for bacterial cultures at different time points and glucose concentrations:
0 mM □ 0.125 mM ▨ 0.25 mM 0.5 mM 1 mM 2 mM 4 mM
8 mM 10 mM ■.
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showed that the proportion of the day spent with
interstitial glucose above the airway threshold was
significantly greater in CF-related diabetes than CF-
normal glucose tolerance (p<0.0001) and healthy volun-
teers (p<0.0001) but was not significantly different
between CF-normal glucose tolerance and healthy
volunteers. Additionally people with CF-related diabetes
spent 29±23% of the day (n=9) with interstitial
glucose≥10 mmol L−1.
3.3. Effect of glucose at airway concentrations on bacterial
growth in vitro
3.3.1. Staphylococcus aureus
Addition of increasing glucose concentrations (0.125–
10 mmol L−1) to S. aureus cultures in nutrient peptone broth
stimulated bacterial growth, with effect apparent after 24 and
48 h of bacterial culture (Fig. 4A). Linear regression showed
that growth was dependent on both glucose concentration in
the range tested and time (R=0.829, p<0.0001), and that
glucose (p<0.0001) and time (p<0.0001) independently
affected bacterial growth. Staphylococcal growth was
significantly greater than control at glucose concentrations>
0.5 mmol L−1 at 24 h (p=0.006) and >8 mmol L−1 at 48 h
(p<0.0001) (Fig. 5).3.3.2. Pseudomonas aeruginosa
Addition of increasing glucose concentrations (0.125–
10 mmol L−1) to Ps. aeruginosa cultures in nutrient peptone
broth stimulated bacterial growth, with effect apparent after
24 and 48 h of bacterial culture (Fig. 4B). Linear regression
showed that growth was dependent on both glucose
concentration in the range tested and time (R=0.969,
p<0.0001), and that glucose (p<0.001) and time (p<
0.0001) independently affected bacterial growth. Pseudomo-
nal growth was significantly greater than control at glucose
Fig. 5. Box plots of growth ratios for Staphylococcus aureus and Pseudomonas aeruginosa at different glucose concentrations compared to no added glucose
after 24 and 48 h. Growth ratios were calculated by dividing OD620 measurements at 24 and 48 h for Staphylococcus aureus and Pseudomonas aeruginosa
grown at each glucose concentration by OD620 for the same organism grown without glucose at each time point. Box plots indicate median, quartiles and extreme
values (open circles) for OD620 ratios. ⁎p<0.05, ⁎⁎p<0.01, ⁎⁎⁎⁎p<0.0001 indicate significant differences in growth from control.
106 A.L. Brennan et al. / Journal of Cystic Fibrosis 6 (2007) 101–109concentrations≥4 mmol L−1 at 24 h (p=0.039) and at
1 mmol L−1 at 48 h (borderline significance, p=0.055)
(Fig. 5).
4. Discussion
We investigated the hypothesis that airway glucose
concentrations would be elevated in people with CF when
blood glucose concentrations exceeded the airway thresh-
old (≥8 mmol L−1) identified in healthy volunteers [8]
and patients on intensive care [9]. People with CF who had
blood glucose≥8 mmol L− 1 had glucose in nasal
secretions more often and at higher concentrations (Fig.
1) than those with blood glucose<8 mmol L−1. These
findings support the use of blood glucose≥8 mmol L−1 as
a surrogate marker for elevated airway glucose concentra-
tions in CF patients. Blood glucose was ≥8 mmol L−1 for
considerable proportions of the day in people with CF-
related diabetes (49±25%) and for less of the day in
people with CF who had normal glucose tolerance (6±5%)
and in healthy volunteers (1±3%). This implies thatairway glucose concentrations are elevated for around half
of the day in people with CF-related diabetes.
We have previously determined the relationship between
blood and nasal glucose concentrations in healthy volun-
teers, finding that nasal glucose was detectable above a blood
glucose concentration of 7.9±1.1 mmol L−1 and rose in
parallel with blood glucose above this concentration.
Furthermore when blood glucose fell, nasal glucose was
removed against a concentration gradient [8]. These
observations imply that an active, saturable glucose transport
process is involved in removal of glucose from the airway
lumen. mRNA and protein expression of a sodium–glucose
co-transporter (SGLT), which transports glucose down a
sodium gradient generated by the use of ATP, has been
identified in animal and human airway epithelium [13–15]
and sodium glucose co-transporters contribute to glucose
removal from the lung lumen in animal models [16]. Flux
equations predict that movement of glucose into the lung
lumen will increase as blood glucose rises [17]. SGLT
activity will initially be able to increase in response to this,
however when the maximum glucose transport capacity of
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glucose concentration at which this point is reached is the
airway glucose threshold.
Paired blood and nasal glucose measurements in people
with CF suggest that the airway glucose threshold is similar
in people with CF to that previously identified in people
without CF [8]. This implies that if SGLT is responsible for
glucose clearance from airway secretions its function is not
impaired in CF. Nasal glucose concentrations in people with
CF were 0.5–3 mM, which were lower than nasal glucose
concentrations in people with diabetes mellitus or intubated
on intensive care [9]. This could simply be explained by
differences in blood glucose concentrations between the
studies, there being only 4 people in the present study with
blood glucose>11 mmol L−1, or by loss of activity of
glucose oxidase coating sticks between studies, although all
sticks were used before the manufacturers expiry date.
Alternatively increased transepithelial sodium transport in
people with CF could drive increased glucose clearance from
CF airways by SGLT. We were unable to identify published
studies of SGLT function in CF airways.
4.1. Limitations of study
We chose to measure airway glucose concentrations in
nasal secretions in this study, as this is a simple, minimally-
invasive technique that has been validated in our laboratory
[8,9]. Glucose oxidase sticks were comparable to a glucose
analyser (Analox GM9D, London, UK) in quantification of
0.5–3 mmol L−1 glucose in airway secretions, being less
accurate outside this range [9]. This technique also changed
the volume and composition of secretions less than other
methods used to sample airway secretions [18]. We have
previously shown strong concordance in the presence or
absence of glucose between nasal and endotracheal secre-
tions in patients intubated on intensive care (p<0.001),
suggesting that nasal glucose can be a surrogate marker for
glucose in lower airway secretions [9]. However a limitation
of our study is that we did not measure lower airway glucose
concentrations directly and the relationship between nasal
and lower airway glucose concentrations in CF has not been
established. Airway glucose concentrations are elevated
where the airway epithelium is inflamed [9]. In CF, epithelial
inflammation is almost invariable in pulmonary epithelium,
but less prevalent in nasal epithelium [19]. The concordance
between nasal and lower airway glucose may therefore be
less strong in people with CF than in other groups and simple
non-invasive methods for measurement of glucose in lower
airway secretions are required to extend this study.
We determined the proportion of the day participants spent
with blood glucose≥8 mmol L−1 as an estimate of daily
airway glucose load. Blood glucose monitoring had advan-
tages over repeat airway glucose measurements as it did not
require investigator intervention, allowing study participants
to eat and take treatment normally. Repeat nasal glucose
measurements could have overestimated airway glucoseconcentrations as nasal glucose concentrations increase after
5 or more measurements, possibly due to microscopic trauma
[8]. We chose blood glucose≥8 mmol L−1 as a surrogate
marker for elevated airway glucose as the mean airway
glucose threshold in healthy volunteers was 7.9 mmol L−1.
Although airway glucose was present more frequently and at
higher concentrations in people with cystic fibrosis when
blood glucose was ≥8 mmol L−1, this threshold did not
absolutely predict the presence or absence of glucose in
airway secretions. As the glucose concentration of airway
secretions is determined not only by the plasma–lumen
glucose gradient, but also by epithelial permeability [9] and
surface area and by glucose transport [17], the airway glucose
threshold will vary between individuals depending on these
characteristics. In healthy volunteers the airway glucose
threshold varied from 6.7 to 9.7 mmol L−1 [8] and this
variability may be similar or greater in people with CF.
However as people with CF-related diabetes spent 49±25%
of the day with blood glucose≥8 mmol L−1 and 29±23% of
the day with blood glucose>10 mmol L−1, airway glucose is
likely to be elevated for significant proportions of the day in
this group, even allowing for individual variability in airway
thresholds.
4.2. Effect of elevated airway glucose concentrations
The effect of elevated glucose concentrations in the
airway is not known. We have previously shown in intubated
patients on intensive care (ICU) that the presence of glucose
in bronchial aspirates was significantly associated with
acquisition of respiratory pathogens, particularly methicillin-
resistant S. aureus (MRSA) [10]. We therefore determined
the effect of glucose at airway concentrations on the growth
of CF respiratory pathogens. Glucose at concentrations
tested had an additional effect on bacterial growth in the
presence of adequate supplies of other nutrients in peptone
broth (Figs. 4 and 5). Growth of S. aureus was significantly
different from control in cultures containing ≥0.5 mmol L−1
glucose at 24 h and ≥8 mmol L−1 at 48 h. Growth of Ps.
aeruginosa was significantly different from control in
cultures containing ≥4 mmol L−1 glucose at 24 h and
≥1 mmol L−1 at 48 h. Our observation that glucose affected
bacterial growth after 24 h, but not 6 h of culture indicates
that glucose altered the final amount but not rate of
growth, although we did not assess growth rate between 6
and 24 h.
This study has a number of limitations. Optical density is
an accurate method of assessing growth of both S. aureus
and Ps. aeruginosa in laboratory culture [12], but is unable
to distinguish between living (potentially pathogenic) and
dead organisms. Furthermore studies of organisms in vitro
may miss variations in virulence that can occur during
infection in vivo [20]. Glucose stimulated bacterial growth in
nutrient peptone broth, but may have different effects in
airway secretions containing different nutrients, antimicro-
bial enzymes and immune proteins. Glucose was added to
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replenished, probably accounting for the effect of low
glucose concentrations on S. aureus growth at 24 h, but not
at 48 h. As people with CF-related diabetes spend 49±25%
of the day with blood glucose above the airway glucose
threshold, airway glucose concentrations may constantly be
topped up in vivo. Culture conditions may also have
accounted for the different effects of glucose on Staphylo-
coccal and Pseudomonal growth. Cultures were stationary
and only agitated for resuspension during measurement of
optical density, which may have limited their aeration. These
conditions may have been more suitable for growth of S.
aureus, which is a facultative anaerobe [21], than for Ps.
aeruginosa, which is strictly aerobic [22]. Future studies of
the effects of glucose on Pseudomonal growth should ensure
aeration, better to mimic conditions in human lung.
Despite their limitations our results raise the possibility
that glucose in the airways could promote or sustain pathogen
growth, allowing development of pulmonary infection, and
may have contributed to the acquisition of MRSA in ICU
patients [10]. The relevance of this is less clear in patients
with cystic fibrosis. In a cross-sectional analysis of 7566
patients on the European Epidemiologic Registry of Cystic
Fibrosis the difference in lung function between diabetic and
non-diabetic CF patients was not linked to presence or
absence of any specific pathogen in the lower respiratory tract
[5]. However Lanng and colleagues found that after insulin
therapy, the percentage of sputum examinations positive for
Haemophilus influenzae and Streptococcus pneumoniae
decreased in diabetic patients [23]. The effect of glucose or
diabetes on the quantity or behaviour of bacteria in CF
airways is not known. In laboratory culture glucose increased
transcription of the algD gene and alginase production by a
mucoid Ps. aeruginosa strain [24].
Elevated glucose concentrations in the airway could have
effects in the lungs of CFRD patients other than through
promoting bacterial growth. Increased glucose concentra-
tions could impair host immune function. Decreased
neutrophil and macrophage chemotaxis, phagocytosis and
killing and impairment in complement and cytokine
responses to infection have been well documented in patients
with diabetes mellitus [25]. Immunoglobulins [26] and
collectins [27], readily undergo non-enzymatic glycosylation
when glucose concentrations are elevated, and these
modifications have been associated with decreased efficacy
against infection [26,28]. Alternatively elevated glucose
concentrations could upregulate the inflammatory response
to pulmonary infection. Experimental elevation of blood
glucose stimulated acute increases in plasma IL-6, TNF-α
and IL-8 in volunteers and septic patients [29–31]. Diabetes
has also been associated with biochemical and structural
changes in the lung, including increased levels of advanced
glycation end-products, derangement of bronchial mucus
production and changes in the basement membranes of
alveolar and bronchial epithelium and pulmonary capillaries
[32].4.3. Implications
In CF patients, airway glucose concentrations are elevated
when blood glucose exceeds the airway threshold (≥8 mmol
L−1) and are correlated with blood glucose concentrations.
As patients with CF-related diabetes spend almost half of the
day with blood glucose above the airway threshold, airway
glucose concentrations may be persistently elevated in
people with CF-related diabetes. Additionally CF patients
with glucose intolerance will also have blood glucose above
the airway threshold prior to the development of diabetes for
between 6% (CF-normal glucose tolerance) and 48% (CF-
related diabetes) of the day.
Pulmonary decline in cystic fibrosis accelerates up to
6 years prior to the development of diabetes and the rate is
proportional to the degree of glucose intolerance. Further
studies are required to determine whether elevated airway
glucose concentrations contribute to this accelerated pul-
monary decline by increasing airway bacterial load,
promoting inflammation or through other mechanisms.
However if glucose in airway secretions truly contributes
to acceleration of pulmonary decline, then treatment targets
for diabetes and glucose intolerance in patients with CF [33]
may need to be revised.
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